The results showed that the level of METTL16 in GC tissues was significantly higher than that in paired NATs (Figure 1A), and the mRNA level of METTL16 in different stages (N0‐N4) of GC patients was significantly higher than that in normal tissues (Figure 1B). This evidence concerns the gene METTL16 and gastric cancer.